Omnicom Wins Novo Nordisk's $520 Million U.S. Media Account
Novo Nordisk has named Omnicom as agency of record for its U.S. media planning and buying, a spokesperson for the Danish drugmaker confirmed to Adweek. The company manufactures the GLP-1 medications Ozempic and Wegovy. COMvergence values the U.S. account at $520 million within a global Novo Nordisk media relationship worth $618 million. The spokesperson said the company looks forward to working with Omnicom "as we continue to scale consumer-focused strategies and connect with patients through emerging channels and technologies, helping bring even greater awareness of our medicines to people living with chronic conditions such as obesity and diabetes."
A budget swing of $520 million reshapes competitive stakes for the next round of pharmaceutical media reviews, since holding companies chasing DTC healthcare dollars now benchmark themselves against Omnicom's expanded book. COMvergence's $618 million figure for the full global relationship signals how large Novo Nordisk's marketing operation has grown, giving Omnicom added weight in negotiations with media owners across the channels Novo Nordisk uses to reach patients living with obesity and diabetes.